Literature DB >> 10986188

Migraine: pharmacotherapy in the emergency department.

A M Kelly1.   

Abstract

Migraine can be a disabling condition for the sufferer. For the small number of patients for whom home therapy fails and who seek treatment in an emergency department, several therapeutic options are available. I review the evidence regarding the effectiveness and safety of the following therapies: the phenothiazines, lignocaine (lidocaine), ketorolac, the ergot alkaloids, metoclopramide hydrochloride, the "triptans," haloperidol, pethidine (meperidine hydrochloride), and magnesium sulfate. Based on available evidence, the most effective agents seem to be prochlorperazine, chlorpromazine and sumatriptan, each of which has achieved greater than 70% efficacy in several studies.

Entities:  

Mesh:

Year:  2000        PMID: 10986188      PMCID: PMC1071066          DOI: 10.1136/ewjm.173.3.189

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  50 in total

Review 1.  Acute migraine therapy: the newer drugs.

Authors:  J Schoenen
Journal:  Curr Opin Neurol       Date:  1997-06       Impact factor: 5.710

2.  Ketorolac vs chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial.

Authors:  M Shrestha; R Singh; J Moreden; J E Hayes
Journal:  Arch Intern Med       Date:  1996 Aug 12-26

3.  Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial.

Authors:  M Maizels; B Scott; W Cohen; W Chen
Journal:  JAMA       Date:  1996 Jul 24-31       Impact factor: 56.272

4.  Intravenous magnesium sulfate rapidly alleviates headaches of various types.

Authors:  A Mauskop; B T Altura; R Q Cracco; B M Altura
Journal:  Headache       Date:  1996-03       Impact factor: 5.887

5.  A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine.

Authors:  J Touchon; L Bertin; A J Pilgrim; E Ashford; A Bès
Journal:  Neurology       Date:  1996-08       Impact factor: 9.910

6.  Electromyographical ischemic test and intracellular and extracellular magnesium concentration in migraine and tension-type headache patients.

Authors:  G Mazzotta; P Sarchielli; A Alberti; V Gallai
Journal:  Headache       Date:  1996-06       Impact factor: 5.887

7.  Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group.

Authors:  R M Gallagher
Journal:  Arch Neurol       Date:  1996-12

8.  A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group.

Authors:  M S Kramer; D Matzura-Wolfe; A Polis; A Getson; P G Amaraneni; M P Solbach; W McHugh; J Feighner; S Silberstein; S A Reines
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

9.  Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache.

Authors:  J Jones; S Pack; E Chun
Journal:  Am J Emerg Med       Date:  1996-05       Impact factor: 2.469

10.  A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.

Authors:  P Winner; O Ricalde; B Le Force; J Saper; B Margul
Journal:  Arch Neurol       Date:  1996-02
View more
  1 in total

Review 1.  New drugs for migraine.

Authors:  Lars Jacob Stovner; Erling Tronvik; Knut Hagen
Journal:  J Headache Pain       Date:  2009-10-01       Impact factor: 7.277

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.